Eleusis Is Researching The Transformation of Psychedelics Into Medicines

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Eleusis is a disruptive life science engine founded in 2013, dedicated to enabling therapeutic solutions across a diverse spectrum of unmet needs by harnessing the untapped potential of psychedelics as medicines. The company’s experienced leadership, world-class advisors, superior IP portfolio, and refined commercial model has helped establish the company at the forefront of psychedelic science and medicine.

Eleusis is developing three clinical-stage candidates optimized for rapid regulatory approval in areas of major unmet need; multiple data readouts between 2021-2023, in the areas of psychiatry, ophthalmology, and neurology, and is uniquely positioned to realize the full therapeutic potential of this promising area of clinical development.

Chairman and Founder of Eleusis, Shlomi Raz, will be presenting at the upcoming Benzinga Virtual Deal Room to discuss the company and its transformative research.

To learn more about this exciting opportunity in the emerging area of psychedelic medicine, you can sign up for Benzinga’s Virtual Deal Room by clicking here.

Photo by Joshua Humpfer on Unsplash

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.